Fabrication Of Hydroxyapatite Nanocarrier For Targeted Drug Release

In the treatment of tumors,most chemotherapeutic drugs(e.g.,doxorubicin,satraplatin,camptothecin,capecitabine,and mitomycin)are distributed to the whole body and do not usually provide rate-controlled release or target specificity.In many cases,conventional drug therapy requires the potentially toxic administration of drug concentrations and results in undesired side effects,such as loss of digestive capacities and appetite,loss of hair,and damage of immune function.In order to overcome the above shortcomings,in recent years,drug nanocarriers have mainly been developed for targeted therapy.Targeting groups-modified and stimulates-responsived nanocarriers can be selectively enter into the cancer cells by endocytosis to release drugs,and almost no damage to normal cells.At present,The inorganic material hydroxyapatite with good biocompatibility,which is the main inorganic constituent of bones and teeth,is widely used as a drug nanocarrier for the treatment of tumors.In this paper,we prepared the the functional hydroxyapatite for targeted drug delivery,and all the relative studies are outline as follows.(1)Folic acid modified hydroxyapatite nanocarrier(FA@DOX@HAP)with good biocompatibility was synthesized for the targeted drug release.FA@DOX@HAP showed a uniform rod shape with an average length of 75 nm and an average particle size of 16 nm.The drug loading content was 33.2 mg/g.At the same time,the nanocarrier can be rapidly(about 15 minutes)enter into the cancer cells with overexpressed folate receptors on their surfaces by endocytosis.The in vitro tissue imags were carried out,due to the strong penetrating ability of the nanocarrier.The results of in vivo anti-tumor efficacy test of nanocarrier indicate that it is possible for the clinical application of nanotechnology.(2)Hyaluronic acid modified hydroxyapatite/silica nanocarrier(DOX@HA@HAP/SiO2)with good biocompatibility was synthesized for the targeted drug release.DOX@HA@HAP/SiO2 had a spherical shape with an average diameter of 70 nm,and the drug loading content was about 43.9 mg/g.The nanocarrier can be rapidly(about 15 minutes)enter into the cancer cells with overexpressed CD44 receptors on their surfaces by endocytosis.The in vitro tissue imags were carried out,due to the strong penetrating ability of the nanocarrier.With the introduction of hydroxyapatite which is easily degradable under acidic conditions,promoting the degradation of silica.which provide a good platform for the design of other inorganic nanocomposites.